Sex-related Differences In Cardiac Involvement In Wild-type Transthyretin Amyloidosis
Courtney S. Campbell(The Ohio State University), Leslie Amass(Pfizer (United States)), Doug Chapman(Pfizer (United States)), Samantha LoRusso(Ohio University), Mathew S. Maurer(Alnylam Pharmaceuticals (United States)), Angela Dispenzieri(Mayo Clinic), Arnt V. Kristen(Heidelberg University), Brian Drachman(Penn Presbyterian Medical Center), Martha Grogan(Mayo Clinic in Arizona), Olivier Lairez(Hôpital Rangueil), Pablo García‐Pavía(Universidad Francisco de Vitoria), Claudio Rapezzi(University of Ferrara)
Cited by 0
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k